Guiding Antibiotic Therapy with Machine Learning: Real-World Applications of a CDSS in Bacteremia Management
Uložené v:
| Názov: | Guiding Antibiotic Therapy with Machine Learning: Real-World Applications of a CDSS in Bacteremia Management |
|---|---|
| Autori: | Juan Carlos Gómez de la Torre, Ari Frenkel, Carlos Chavez-Lencinas, Alicia Rendon, Yoshie Higuchi, Jose M. Vela-Ruiz, Jacob Calpey, Ryan Beaton, Isaac Elijah, Inbal Shachar, Everett Kim, Sofia Valencia Osorio, Jason James Lee, Gabrielle Grogan, Jessica Siegel, Stephanie Allman, Miguel Hueda-Zavaleta |
| Zdroj: | Life, Vol 15, Iss 11, p 1756 (2025) |
| Informácie o vydavateľovi: | MDPI AG |
| Rok vydania: | 2025 |
| Zbierka: | Directory of Open Access Journals: DOAJ Articles |
| Predmety: | artificial intelligence, clinical decision support systems, bacteremia, antimicrobial stewardship, machine learning, Science |
| Popis: | Bacteremia is a life-threatening condition contributing significantly to sepsis-related mortality worldwide. With delayed appropriate antibiotic therapy, mortality increases by 20% regardless of antimicrobial resistance. This study evaluated the perceived clinical utility of Artificial Intelligence (AI)-powered Clinical Decision Support Systems (CDSSs) (OneChoice and OneChoice Fusion) among specialist physicians managing bacteremia cases. A cross-sectional survey was conducted with 65 unique specialist physicians from multiple medical specialties who were presented with clinical vignettes describing patients with bacteremia and 90 corresponding AI-CDSS recommendations. Participants assessed the perceived helpfulness of AI decision-making, the impact of AI recommendations on their own clinical judgment, and the concordance between AI recommendations and their own clinical judgment, as well as the validity of changing therapy based on CDSS recommendations. The study encompassed a diverse range of bacterial pathogens, with Escherichia coli representing 38.7% of the isolates and 30% being extended-spectrum β-lactamase (ESBL) producers. Findings show that 97.8% [(95% CI: 92.2–99.7%)] of physicians reported that AI facilitated decision-making and substantial concordance (87.8% [95% CI: 79.2–93.7%; Cohen’s κ = 0.76]) between AI recommendations and physicians’ therapeutic recommendations. Stratification by pathogen revealed the highest concordance for Escherichia coli bacteremia (96.6%, 28/29 cases). Implementation analysis revealed a meaningful clinical impact, with 68.9% [(95% CI: 58.3–78.2%)] of cases resulting in AI-guided treatment modifications. These findings indicate that AI-powered CDSSs effectively bridge critical gaps in infectious disease expertise and antimicrobial stewardship, providing clinicians with evidence-based therapeutic recommendations that can be integrated into routine practice to optimize antibiotic selection, particularly in settings with limited access to infectious disease specialists. For ... |
| Druh dokumentu: | article in journal/newspaper |
| Jazyk: | English |
| Relation: | https://www.mdpi.com/2075-1729/15/11/1756; https://doaj.org/toc/2075-1729; https://doaj.org/article/e692140d2520409f82ea942efeda9623 |
| DOI: | 10.3390/life15111756 |
| Dostupnosť: | https://doi.org/10.3390/life15111756 https://doaj.org/article/e692140d2520409f82ea942efeda9623 |
| Prístupové číslo: | edsbas.7AFDBBDB |
| Databáza: | BASE |
Nájsť tento článok vo Web of Science | Abstrakt: | Bacteremia is a life-threatening condition contributing significantly to sepsis-related mortality worldwide. With delayed appropriate antibiotic therapy, mortality increases by 20% regardless of antimicrobial resistance. This study evaluated the perceived clinical utility of Artificial Intelligence (AI)-powered Clinical Decision Support Systems (CDSSs) (OneChoice and OneChoice Fusion) among specialist physicians managing bacteremia cases. A cross-sectional survey was conducted with 65 unique specialist physicians from multiple medical specialties who were presented with clinical vignettes describing patients with bacteremia and 90 corresponding AI-CDSS recommendations. Participants assessed the perceived helpfulness of AI decision-making, the impact of AI recommendations on their own clinical judgment, and the concordance between AI recommendations and their own clinical judgment, as well as the validity of changing therapy based on CDSS recommendations. The study encompassed a diverse range of bacterial pathogens, with Escherichia coli representing 38.7% of the isolates and 30% being extended-spectrum β-lactamase (ESBL) producers. Findings show that 97.8% [(95% CI: 92.2–99.7%)] of physicians reported that AI facilitated decision-making and substantial concordance (87.8% [95% CI: 79.2–93.7%; Cohen’s κ = 0.76]) between AI recommendations and physicians’ therapeutic recommendations. Stratification by pathogen revealed the highest concordance for Escherichia coli bacteremia (96.6%, 28/29 cases). Implementation analysis revealed a meaningful clinical impact, with 68.9% [(95% CI: 58.3–78.2%)] of cases resulting in AI-guided treatment modifications. These findings indicate that AI-powered CDSSs effectively bridge critical gaps in infectious disease expertise and antimicrobial stewardship, providing clinicians with evidence-based therapeutic recommendations that can be integrated into routine practice to optimize antibiotic selection, particularly in settings with limited access to infectious disease specialists. For ... |
|---|---|
| DOI: | 10.3390/life15111756 |